Neurovance Emerges From Stealth With $7 Million for ADHD
Published: Oct 18, 2012
Neurovance recently completed its phase 1 clinical trial of EB-1020, its norepinephrine and dopamine-preferring reuptake inhibitor, that evaluated single and multiple ascending doses in normal subjects. EB-1020 was well tolerated and demonstrated a wide therapeutic index.
EB-1020 is being developed for adult ADHD due to its potent norepinephrine (NE) reuptake inhibition, combined with moderate dopamine (DA) reuptake inhibition and very modest serotonin (5-HT) reuptake inhibition. This suggests EB-1020 has a profile similar to the pharmacology of the leading non-stimulant atomoxetine given in combination with methylphenidate, one of the leading stimulants. Unlike stimulants, however, EB-1020 may have a low risk of drug abuse liability, as suggested by preclinical and clinical data. The ADHD market is valued at $7 billion and stimulants are the leading medications used for ADHD. However, stimulants used to treat ADHD are highly addictive and are tightly regulated by the government, which has led to shortages in the last few years.
“Given the favorable initial results showing good tolerability in healthy subjects and the expected pharmacodynamic profile associated with the broad pharmacology of EB-1020, we are now conducting work leading to our first patient trial, a phase 2a pilot study in adult ADHD planned for next year,” said Anthony A. McKinney, President and CEO of Neurovance. “Several members of our management group were closely involved in the development of Strattera, the first non-stimulant for ADHD, and we are well positioned to build from that experience.”
Novartis Venture Fund led this new round of investment where all existing investors participated including: Venture Investors, H&Q Healthcare Investors (HQH) and H&Q Life Sciences Investors (HQL), GBS Venture Partners, State of Wisconsin Investment Board (SWIB) and Timothy J. Barberich.
“This novel norepinephrine and dopamine-preferring reuptake inhibitor has the potential to become a preferred treatment for adults with ADHD because it modulates two of the most important neurotransmitters relevant to ADHD,” said Campbell Murray, M.D., Chairman of Neurovance.
Dr. Murray added, “We conducted substantial due diligence for this new investment and believe that EB-1020 has the potential to impact several of the co-morbidities associated with ADHD, including anxiety, depression and emotional dysregulation. If these benefits can be proven then EB-1020 could become an important addition to the therapeutic armamentarium because most adults with ADHD have one or more of these co-morbidities.”
About Neurovance, Inc.
Neurovance has been spun out of Euthymics Bioscience, Inc. to advance EB-1020, a norepinephrine and dopamine-preferring reuptake inhibitor for ADHD. In addition to EB-1020, Neurovance also holds a substantial portfolio of research stage reuptake inhibitors.
Euthymics and Neurovance are private corporations with common headquarters in Cambridge, Massachusetts. Additional information can be found on the Euthymics website at www.euthymics.com.
Anthony A. McKinney, 617-758-0300
Media: Initiate PR
Jennifer Anderson (New York), 646-237-6926
Stephen Gendel (Los Angeles), 310-878-4652